ResultsIQ

ResultsIQ › Latest results › SMS Pharmaceuticals Limited

SMS Pharmaceuticals Limited Q2 FY27 results deck summary

NSE: SMSPHARMA · BSE: 532815

Results deck of 4 Nov 2026, summarised by AI from the filing.

SMS Pharmaceuticals Q2 FY27 revenue ₹316.08 cr, up 30% YoY, with FY27 revenue growth and EBITDA margins now expected to exceed earlier guidance.

Key takeaways

  1. FY27 outlook Management expects FY27 revenue growth and EBITDA margins to exceed earlier guidance, without stating new figures.
  2. Margin step-up EBITDA margin expanded 145 bps YoY to 21% and gross margin including manufacturing expenses rose to 35%.
  3. Backward integration Backward integration lowered raw material dependency on China and lifted gross margin to 35%.
  4. Gross margin dip Gross margin fell 114 bps QoQ to 35% in Q2 FY27 from 36% in Q1 FY27.

Original filing on BSE

SMS Pharmaceuticals Limited Q2 FY27 results

As filed: Revenue ₹316 cr (+31% year on year), EBITDA ₹67.7 cr (+38% year on year), PAT ₹39.9 cr (+59% year on year), EBITDA margin 21.4% (+116 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹207 cr (+6% year on year), EBITDA ₹41.0 cr (+5% year on year), PAT ₹20.9 cr (+5% year on year), EBITDA margin 19.8% (−11 bps). Score 27 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 11 bps year on year. Revenue fell 13% from last quarter. Profit rose ₹0.9 cr on a year ago, against ₹4.0 cr the year before. Share price after the results: −4.9% in 28 days (Nifty 500: +0.3%).
  • Q4 FY26: Revenue ₹238 cr (−4% year on year), EBITDA ₹39.9 cr (−5% year on year), PAT ₹32.7 cr (+64% year on year), EBITDA margin 16.8% (−16 bps). Score 32 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was in line with it. EBITDA margin fell 16 bps year on year. Consolidated profit +64% but standalone 0%. Profit rose ₹12.7 cr on a year ago, more than the ₹3.0 cr it added the year before. Share price after the results: −11.1% in 28 days (Nifty 500: +2.4%).
  • Q3 FY26: Revenue ₹210 cr (+22% year on year), EBITDA ₹43.7 cr (+32% year on year), PAT ₹23.5 cr (+30% year on year), EBITDA margin 20.7% (+167 bps). Score 65 of 100, Above trend. Revenue and EBITDA growth were in line with the company's own trend; profit growth was below it. EBITDA margin rose 167 bps year on year. Revenue fell 13% from last quarter. Profit rose ₹5.5 cr on a year ago, against ₹7.0 cr the year before. Share price after the results: +20.7% in 30 days (Nifty 500: −5.9%).
  • Q2 FY26: Revenue ₹242 cr (+23% year on year), EBITDA ₹49.0 cr (+48% year on year), PAT ₹25.0 cr (+79% year on year), EBITDA margin 20.3% (+350 bps). Score 80 of 100, Above trend. Revenue and profit growth were in line with the company's own trend; EBITDA growth was well above it. EBITDA margin rose 350 bps year on year. Revenue rose ₹45.0 cr on a year ago, more than the ₹30.0 cr it added the year before. Share price after the results: +10.6% in 30 days (Nifty 500: 0.0%).
  • Q1 FY26: Revenue ₹196 cr (+20% year on year), EBITDA ₹39.0 cr (+15% year on year), PAT ₹20.0 cr (+25% year on year), EBITDA margin 19.9% (−83 bps). Score 39 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 83 bps year on year. Revenue fell 21% from last quarter. Revenue rose ₹32.0 cr on a year ago, more than the ₹29.0 cr it added the year before. Share price after the results: +8.9% in 30 days (Nifty 500: +1.9%).
  • Q4 FY25: Revenue ₹248 cr (+1% year on year), EBITDA ₹42.0 cr (+24% year on year), PAT ₹20.0 cr (+18% year on year), EBITDA margin 16.9% (+311 bps). Score 44 of 100, In line with trend. Revenue and EBITDA growth were below the company's own trend; profit growth was well below it. EBITDA margin rose 311 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −5.9% in 28 days (Nifty 500: +3.6%).
  • Q3 FY25: Revenue ₹173 cr (+7% year on year), EBITDA ₹33.0 cr (+10% year on year), PAT ₹18.0 cr (+64% year on year), EBITDA margin 19.1% (+44 bps). Score 35 of 100, Below trend. Revenue and profit growth were below the company's own trend; EBITDA growth was well below it. EBITDA margin rose 44 bps year on year. Revenue fell 12% from last quarter. Profit rose ₹7.0 cr on a year ago, against ₹7.0 cr the year before.

Past price moves after results do not indicate future moves. Not a recommendation.

SMS Pharmaceuticals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.